Qure.ai & Microsoft partner on lung cancer AI imaging
Qure.ai has partnered with Microsoft to integrate its artificial intelligence-powered lung cancer detection and management tools into Microsoft's Precision Imaging Network.
The Qure.ai suite uses large language models and Agentic AI for lung cancer detection, measurement and management. Its tools coordinate the activities of a range of clinical teams, from radiologists to thoracic surgeons, supporting a faster route from early detection to treatment. The organisation says this tech can streamline hospital workflows and extend the use of AI technologies in patient care.
According to the American Cancer Society, lung cancer remains the leading cause of cancer deaths in the US, accounting for more fatalities than colon, breast and prostate cancers combined.
Enhanced hospital access
Bringing Qure.ai's solutions onto Microsoft's cloud-based Precision Imaging Network is expected to simplify deployment for health systems. Hospitals in the United States will be able to access the AI suite for a range of applications, including early nodule detection on chest X-rays, measurement via CT scans, and management tracking. Qure.ai offers its products either as standalone solutions or as a unified workflow suite.
The technology also extends to emergency triage for neurocritical findings, aiming to prioritise urgent care cases in hospitals.
"The Qure.ai and Microsoft collaboration brings new levels of choice and simplicity for hospitals and health systems across the USA. It will power-up access to early detection, triage and tracking to improve patient care, boost survival rates and reduce overall healthcare costs," said Jim Mercadante, Chief Commercial Officer, Qure.ai. "It will also bolster a growing global roster of strategic alliances between Qure.ai, academia, governments, pharmaceutical, life science and tech companies, united in advancing the digitization of health."
Mercadante added that through a longstanding partnership with AstraZeneca and the EDISON Alliance, Qure.ai has surpassed five million scans, applying AI to routine chest X-rays across 20 countries.
Global reach
Qure.ai's healthcare AI solutions are deployed across more than 4,800 sites in over 105 countries. The company's lung cancer suite has 19 FDA-cleared findings to support identification, triage and management, and its neurocritical solution is designed to assist with emergency radiology interventions.
The company was included on the TIME 100 Most Influential Companies list for 2025, in recognition of its use of AI to support access to care and diagnostic tools for high-burden diseases worldwide.
"The integration of Qure.ai's AI solutions into the Precision Imaging Network will help health systems unlock new levels of efficiency - from faster detection and diagnosis to more coordinated multidisciplinary care," said Peter Durlach, Corporate VP and Chief Strategy Officer, Microsoft Health and Life Sciences. "This collaboration reflects Microsoft's commitment to empowering healthcare organizations with secure, scalable cloud AI solutions that enable earlier interventions, improved patient outcomes, and drive sustainable transformation across the continuum of care."
